These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Changes of IgG Trzos S; Link-Lenczowski P; Sokołowski G; Pocheć E Front Immunol; 2022; 13():841710. PubMed ID: 35370997 [TBL] [Abstract][Full Text] [Related]
44. Metamorphic thyroid autoimmunity in Down Syndrome: from Hashimoto's thyroiditis to Graves' disease and beyond. Aversa T; Valenzise M; Salerno M; Corrias A; Iughetti L; Radetti G; De Luca F; Wasniewska M Ital J Pediatr; 2015 Nov; 41():87. PubMed ID: 26558364 [TBL] [Abstract][Full Text] [Related]
48. The effect of alemtuzumab on neurodegeneration in relapsing-remitting multiple sclerosis: A five-year prospective mono-center study. Sandgren S; Novakova L; Nordin A; Sabir H; Axelsson M; Malmeström C; Zetterberg H; Lycke J Mult Scler Relat Disord; 2024 Nov; 91():105894. PubMed ID: 39293124 [TBL] [Abstract][Full Text] [Related]
49. Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves' disease. Ze Y; Shao F; Feng X; Shen S; Bi Y; Zhu D; Zhang X BMC Endocr Disord; 2022 Dec; 22(1):319. PubMed ID: 36522617 [TBL] [Abstract][Full Text] [Related]
50. Genetic susceptibility in thyroid autoimmunity. Ban Y; Tomer Y Pediatr Endocrinol Rev; 2005 Sep; 3(1):20-32. PubMed ID: 16369210 [TBL] [Abstract][Full Text] [Related]
51. The Relationship Between Primary Thyroid Lymphoma and Various Types of Thyroid Autoimmunity: A Retrospective Cohort Study of 498 Cases, Including 9 Cases with Graves' Disease. Suzuki N; Watanabe N; Noh JY; Yoshimura R; Mikura K; Kinoshita A; Suzuki A; Mitsumatsu T; Fukushita M; Matsumoto M; Yoshihara A; Katoh R; Sugino K; Ito K Thyroid; 2022 May; 32(5):552-559. PubMed ID: 35229626 [No Abstract] [Full Text] [Related]
52. Low vitamin D status is associated with hypothyroid Hashimoto's thyroiditis. Kim D Hormones (Athens); 2016 Jul; 15(3):385-393. PubMed ID: 27394703 [TBL] [Abstract][Full Text] [Related]
53. Anti-glutamic acid decarboxylase antibody in Graves' disease is a possible indicator for the unlikelihood of going into remission with antithyroid agents. Yoshihara A; Isozaki O; Okubo Y; Takano K Endocr J; 2009; 56(2):269-74. PubMed ID: 19139594 [TBL] [Abstract][Full Text] [Related]
58. A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience. Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF Mult Scler Relat Disord; 2023 Jun; 74():104712. PubMed ID: 37054581 [TBL] [Abstract][Full Text] [Related]
59. Development of thyroid dysfunction and autoantibodies in Graves' multiplex families: an eight-year follow-up study in Chinese Han pedigrees. Hou X; Li Y; Li J; Wang W; Fan C; Wang H; Zhang H; Shan Z; Teng W Thyroid; 2011 Dec; 21(12):1353-8. PubMed ID: 22029718 [TBL] [Abstract][Full Text] [Related]
60. Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity. Bianco A; Nicoletti T; Traini E; Del Giacomo P; Del Gatto V; Lucchini M; Rota CA; Mirabella M J Endocrinol Invest; 2020 Aug; 43(8):1159-1161. PubMed ID: 32130689 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]